European Academy of Dermatology and Venereology (EADV) Congress 2026

Vienna, Austria 30 September 2026 - 03 October 2026

Upadacitinib improves repigmentation in nonsegmental vitiligo

06 Nov 2026 by

Treatment with upadacitinib, an oral Janus kinase (JAK)-selective inhibitor, continues to improve skin repigmentation through week 76 in patients with nonsegmental vitiligo (NSV), according to the phase III Viti-Up-1 and -2 studies presented at EADV 2026.

06 Nov 2026

Trispecific antibody meets EASI-75 target in AD

04 Nov 2026 by

In a two-stage phase II dose-ranging trial, once-monthly treatment with tilrekimig yields high clinical response rates and reduces itching in biologic-naïve adults with mild-to-moderate atopic dermatitis (AD).

04 Nov 2026

Tranquillo data support ritlecitinib for NSV

27 Oct 2026 by

In two pivotal phase III Tranquillo studies, individuals with nonsegmental vitiligo (NSV) achieved significant and clinically meaningful improvements in facial and total body repigmentation after 52 weeks of treatment with oral ritlecitinib.

27 Oct 2026

ARCADIA LTE supports long-term efficacy, safety of nemolizumab for AD

23 Oct 2026 by

The open-label long-term extension (LTE) of the ARCADIA trial demonstrates the safety and efficacy of nemolizumab for up to 152 weeks in adults and adolescents with moderate-to-severe atopic dermatitis (AD).

23 Oct 2026

Delgocitinib cream improves quality of life in teens with chronic hand eczema

19 Oct 2026 by

Adolescents with moderate-to-severe chronic hand eczema report a considerable improvement in their quality of life following treatment with delgocitinib cream, according to data from the international phase III DELTA TEEN study.

19 Oct 2026

Novel oral TYK2 inhibitor beats old in head-to-head plaque psoriasis trial

18 Oct 2026 by

In the treatment of moderate-to-severe plaque psoriasis, the investigational selective tyrosine kinase 2 (TYK2) inhibitor zasocitinib is associated with higher rates of skin clearance compared with the first-generation TYK2 inhibitor deucravacitinib, as shown in the head-to-head phase III LATITUDE Atlas trial.

18 Oct 2026

Secukinumab eases symptoms in moderate-to-severe hidradenitis suppurativa

18 Oct 2026 by

Treatment with secukinumab results in improved clinical response at 12 months and is well tolerated in patients with hidradenitis suppurativa (HS), according to the ongoing SPECTRA study in France.

18 Oct 2026

Long-term denifanstat sustains efficacy, safety for moderate-to-severe acne vulgaris

17 Oct 2026 by

Long-term use of the fatty acid synthase (FASN) inhibitor denifanstat maintains its clinical efficacy in patients with moderate-to-severe acne without compromising their safety, according to a phase III extension study (ASC40-304) presented at EADV 2026.

17 Oct 2026

Five-year lebrikizumab data show sustained disease control in AD

16 Oct 2026 by

Treatment with lebrikizumab maintains improvements in skin and itch over 5 years in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the ADlong long-term extension trial presented at EADV 2026.

16 Oct 2026

Ritlecitinib at year 5: The lesser the baseline scalp hair loss, the greater the response

13 Oct 2026 by

A 5-year analysis of the phase III ALLEGRO-LT study, presented at EADV 2026, shows that patients with the least baseline scalp hair loss respond best and fastest to the Janus kinase (JAK) inhibitor ritlecitinib.

13 Oct 2026